Primary Objectives:~To evaluate the efficacy of TAB014 compared to Lucentis in neovascular age-related macular degeneration patients~Secondary Objectives:~To evaluate the safety of TAB014 compared to Lucentis in neovascular age-related macular degeneration patients.~To evaluate the immunogenicity of TAB014 in neovascular age-related macular degeneration patients.
This study is a randomized, multi-center, double blind, Lucentis controlled non-inferiority study in neovascular age-related macular degeneration patients. The objective of this study is to compare the efficacy and safety of TAB014 and ranibizumab (Lucentis).